Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for Nasdaq:ONTY
-0.02 (-1.52%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.27 - 1.37
52 week 0.90 - 4.69
Open 1.34
Vol / Avg. 984,482.00/1.08M
Mkt cap 121.58M
P/E     -
Div/yield     -
EPS -0.34
Shares 94.96M
Beta 1.80
Inst. own 64%
May 9, 2016
Q1 2016 Oncothyreon Inc Earnings Release (Estimated) Add to calendar
Mar 14, 2016
Q4 2015 Oncothyreon Inc Earnings Release
Mar 8, 2016
Oncothyreon Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.66% -32.63%
Return on average equity -41.67% -37.24%
Employees 53 -
CDP Score - -


2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The Company is developing preclinical product candidates in oncology, and certain rare diseases, using its protocell technology. It also collaborates with partners to discover and develop additional product candidates. The Company is developing a series of orally active Chk1 inhibitors in collaboration with Sentinel Oncology Ltd. The Company is focusing its activities with protocells on the delivery of mini-circle DNA or mRNA to produce proteins intracellularly in specifically targeted organs or cells. It is collaborating with Adimab LLC for the discovery of antibodies against undisclosed immunotherapy targets in oncology.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 45
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Director
Age: 63
Bio & Compensation  - Reuters
Mark Lampert Director
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters